GlobeNewswire by notified

Hexagon Purus ASA: Successful completion of the acquisition of Wystrach and issuance of consideration shares

Share

Reference is made to the stock exchange announcement by Hexagon Purus ASA ("Hexagon Purus" or the "Company") on 30 September 2021, regarding Hexagon Purus' entry into of a share purchase agreement to acquire 100% of Wystrach GmbH ("Wystrach"), a leading European systems and solutions provider for storage and transport of compressed gases (the "Transaction").

Hexagon Purus is pleased to announce that the Transaction has been successfully completed. Consequently, the board of directors of the Company has, pursuant to the authorization granted by the Company's shareholder meeting on 3 November 2020, issued 4,444,430 new shares of Hexagon Purus (the "Consideration Shares") at a subscription price of NOK 33.4343 per share, to the seller as part consideration for the shares of Wystrach.

Following registration of the share capital increase pertaining to the Consideration Shares in the Norwegian Register of Business Enterprises, the Company will have 233 536 669 shares in issue, each of par value NOK 0.10.


Contacts:

Salman Alam, Vice President Corporate Development, Hexagon Purus
Telephone: +47 476 12 713 | salman.alam@hexagonpurus.com

Karen Romer, SVP Communications, Hexagon Composites
Telephone: +47 950 74 950 | karen.romer@hexagongroup.com

About Hexagon Purus:

Hexagon Purus, a Hexagon Composites company, is a world leading provider of hydrogen type 4 high-pressure cylinders, battery packs and vehicle systems integration for fuel cell electric and battery electric vehicles. Hexagon Purus enables zero emission solutions for light, medium and heavy-duty vehicles, buses, ground storage, distribution, maritime, rail and aerospace. Learn more at www.hexagonpurus.com 


About Wystrach:

Founded in 1988 in Weeze, Germany, Wystrach is a full-service provider of high- pressure storage and transportation solutions for hydrogen and other gases. Its portfolio includes stationary bundles; containers of all sizes; tank systems for trains, buses, and trucks; and storage solutions, e.g. for power-to-gas applications. The company also offers a mobile hydrogen refueling station, the WyRefueler, in its range of products. In addition to in-house design and production capabilities, Wystrach offers end-to-end service packages for assembly, commissioning, and maintenance, and also provides support on approval matters. Wystrach is based in the Lower Rhine region of Germany and employs around 185 people

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Intertrust and CSC agree on recommended all-cash offer of EUR 20.00 per share6.12.2021 07:15:00 CET | Press release

JOINT PRESS RELEASE This is a joint press release by Intertrust N.V. ("Intertrust" or the "Company") and Corporation Service Company ("CSC" or the "Offeror") pursuant to the provisions of Section 4, paragraphs 1 and 3, Section 5, paragraph 1 and Section 7, paragraph 4 of the Netherlands Decree in Public Takeover Bids (Besluit openbare biedingen Wft, the "Decree") in connection with the intended recommended public offer (the "Offer") by the Offeror for all the issued and outstanding ordinary shares in the capital of Intertrust. This announcement does not constitute an offer, or any solicitation of any offer, to buy or subscribe for any securities in Intertrust. Any offer will be made only by means of an offer memorandum (the "Offer Memorandum") approved by the AFM. This announcement is not for release, publication or distribution, in whole or in part, in or into, directly or indirectly, the United States, Canada and Japan. Intertrust and CSC agree on recommended all-cash offer of EUR 20

Results of EssilorLuxottica’s mandatory public offer for GrandVision shares6.12.2021 07:00:00 CET | Press release

Results of EssilorLuxottica’s mandatory public offer for GrandVision shares • Acceptance Period ended 3 December 2021 (at 17:40 hours CET) • 13.06% of the Shares have been tendered under the Offer during the Acceptance Period • Including the 86.67% of the Shares already held by the Offeror, the Offeror will hold a total interest of 99.73% • Settlement of the Offer will take place on 8 December 2021, at which date the Offer Price of Euro 28.42 per Share will be paid • Remaining Shares can be tendered during the Post-Acceptance Period, commencing on 7 December 2021 at 09:00 hours CET and ending on 20 December 2021 at 17:40 hours CET Charenton-le-Pont, France and Schiphol, the Netherlands (6 December, 2021 – 7:00am CET) – With reference to the press release of 7 October 2021 by EssilorLuxottica S.A. (the “Offeror“) and GrandVision N.V. (“GrandVision”) regarding the publication of the offer memorandum of the same date (the “Offer Memorandum”) for the recommended mandatory public offer (the

Roche to launch SARS-CoV-2 & Flu A/B Rapid Antigen Test in countries accepting the CE Mark to enable rapid differentiation of viral respiratory infections6.12.2021 07:00:00 CET | Press release

The combination rapid antigen test quickly differentiates between SARS-CoV-2 and influenza viruses A and B infections, with results ready in less than 30 minutes, allowing informed decisions on patient and pandemic management decisionsAffordable and small, instrument-free testing kit enables convenient use for healthcare professionals at different point of care locations and in resource-limited settingsThe test works seamlessly with NAVIFY® Pass, Roche’s digital solution that allows individuals and healthcare professionals to immediately store, display, and share their COVID-19 test results and vaccine status through a unique data matrix Basel, 6 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced its plans to launch the SARS-CoV-2 & Flu A/B Rapid Antigen Test for professional use in markets accepting the CE Mark by the beginning of January. Roche also intends to file for Emergency Use Authorization (EUA) to the U.S. Food and Drug Administration (FDA) in early 2022. The

Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate5.12.2021 18:21:41 CET | Press release

Bavarian Nordic’s non-adjuvanted COVID-19 vaccine candidate, ABNCoV2 (100μg), demonstrated a strong boosting effect, increasing the existing levels of SARS-CoV-2 neutralizing antibodies against the Wuhan variant by 2-40-fold depending on the initial levels of antibodiesThe large boosting effect of ABNCoV2 elevated the neutralizing antibodies to levels reported to be highly efficacious (>90%) against SARS-CoV-21A similar fold increase was observed for all SARS-CoV-2 variants tested (Wuhan, Alpha, Beta and Delta) following the booster vaccination with ABNCoV2The vaccine was well-tolerated, with no serious adverse events reportedThese initial results confirm the potential of ABNCoV2 to function as a universal COVID-19 booster vaccineThe Company’s management will host a conference call tomorrow at 2 pm CET (8 am EST) to discuss the results COPENHAGEN, Denmark, December 5, 2021 – Bavarian Nordic A/S (OMX: BAVA), a fully integrated vaccines company, announced today positive topline results f

Bavarian Nordic rapporterer positive toplinjeresultater fra fase 2-forsøg med sin COVID-19 vaccinekandidat5.12.2021 18:21:41 CET | pressemeddelelse

Bavarian Nordics COVID-19 vaccinekandidat uden hjælpestof (adjuvant), ABNCoV2 (100μg), demonstrerede i et fase 2 forsøg en solid boostereffekt, ved at forhøje de eksisterende niveauer af SARS-CoV-2 neutraliserende antistoffer mod Wuhan varianten 2-40 gange afhængigt af de initiale antistofniveauerDen høje boostereffekt af ABNCoV2 forhøjede niveauet af neutraliserende antistoffer til niveauer som er blevet rapporterede som værende yderst effektive (>90%) mod SARS-CoV-21En lignende forhøjelse blev observeret for alle testede SARS-CoV-2 varianter (Wuhan, Alpha, Beta og Delta) efter boostervaccination med ABNCoV2Vaccinen var veltolereret med ingen rapporterede alvorlige bivirkningerDisse toplinjeresultater bekræfter ABNCoV2’s potentiale til at fungere som en universel COVID-19 boostervaccineVirksomhedens ledelse vil afholde en telefonkonference i morgen kl. 14:00 CET for at diskutere resultaterne KØBENHAVN, Danmark, 5. december 2021 – Bavarian Nordic A/S (OMX: BAVA), et fuldt integreret va

Galapagos increases share capital through subscription right exercises3.12.2021 22:01:00 CET | Press release

Mechelen, Belgium; 3 December 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces a share capital increase arising from subscription right exercises. Galapagos issued 22,600 new ordinary shares on 3 December 2021, for a total capital increase (including issuance premium) of €578,700.00. Pursuant to the subscription right exercise program of Galapagos’ management board, members of the management board automatically are committed to exercise a minimum number of subscription rights, subject to certain conditions. In accordance with the rules of this program, one management board member exercised 5,000 subscription rights. In accordance with Belgian transparency legislation1, Galapagos notes that its total share capital currently amounts to €354,582,005.11, the total number of securities conferring voting rights amounts to 65,552,721, which is also the total number of voting rights (the “denominator”), and all securities conferring voting rights and al

Sampo plc’s share buybacks 03/12/20213.12.2021 21:30:00 CET | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 03/12/2021 at 10:30 pm Sampo plc’s share buybacks 03/12/2021 On 03/12/2021 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)23,68743.29AQEU27,42643.28CEUX4,32043.37TQEX72,59243.31XHELTOTAL128,02543.30 *rounded to two decimals On 1 October 2021, Sampo announced a share buyback programme of up to a maximum of EUR 750 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 4 October 2021, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 6,263,553 Sampo A shares representing 1.13 per cent of the total number of shares in Sampo plc. Detail